PMID- 30603325
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2190-1678 (Print)
IS  - 2190-1686 (Electronic)
IS  - 2190-1678 (Linking)
VI  - 8
IP  - 2
DP  - 2017 Jun
TI  - The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed 
      by computed tomography and on alanine transaminase levels in Japanese patients 
      with type 2 diabetes mellitus.
PG  - 218-227
LID - 10.1007/s13340-016-0302-y [doi]
AB  - We assessed the effects of a 12-week ipragliflozin treatment on the 
      liver-to-spleen attenuation ratio (L/S ratio) using computed tomography and on 
      alanine transaminase (ALT) levels in Japanese patients with type 2 diabetes 
      mellitus (T2DM). Sixty-two patients with T2DM [age, 56 +/- 8 years; hemoglobin A1c 
      (HbA1c) levels, 8.1 +/- 0.9%; body mass index (BMI), 27.5 +/- 3.3 kg/m(2)] were 
      randomly assigned in a 2:1 ratio to receive ipragliflozin (50 mg/day; 
      ipragliflozin group; n = 40) or continued treatment (control group; n = 22) for 
      12 weeks. The primary endpoints were changes in ALT levels; the secondary 
      endpoints included changes in the L/S ratio and in the visceral fat area (VFA) 
      and subcutaneous fat area (SFA) before and after 12 weeks of the treatment as 
      assessed by computed tomography. ALT levels (-12.45 vs. +5.82 IU/l, P < 0.001), 
      L/S ratio (+0.07 vs. -0.08, P < 0.001), SFA (-5.8 vs. +13.3 cm(2), P < 0.05), and 
      VFA (+1.4 vs. +20.4 cm(2), P < 0.05) significantly changed from baseline in the 
      ipragliflozin group compared with the values in the control group. Multiple 
      regression analysis among all subjects revealed that the independent factor 
      contributing to the %DeltaALT and %DeltaL/C ratio was treatment group alone 
      (ipragliflozin group = 1; control group = 0; beta coefficient = -32.08, P < 0.001 
      and beta coefficient = 19.98, P < 0.05, respectively). Thus, ipragliflozin may lower 
      ALT levels associated with increased L/S ratios, indicating its potential 
      therapeutic efficacy in T2DM-associated hepatic steatosis.
FAU - Bando, Yukihiro
AU  - Bando Y
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, 
      Wadanaka-Machi, Fukui, 918-8503 Japan. ISNI: 0000 0004 1774 4989. GRID: 
      grid.415130.2
FAU - Ogawa, Ayumi
AU  - Ogawa A
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, 
      Wadanaka-Machi, Fukui, 918-8503 Japan. ISNI: 0000 0004 1774 4989. GRID: 
      grid.415130.2
FAU - Ishikura, Kazuhide
AU  - Ishikura K
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, 
      Wadanaka-Machi, Fukui, 918-8503 Japan. ISNI: 0000 0004 1774 4989. GRID: 
      grid.415130.2
FAU - Kanehara, Hideo
AU  - Kanehara H
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, 
      Wadanaka-Machi, Fukui, 918-8503 Japan. ISNI: 0000 0004 1774 4989. GRID: 
      grid.415130.2
FAU - Hisada, Azusa
AU  - Hisada A
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, 
      Wadanaka-Machi, Fukui, 918-8503 Japan. ISNI: 0000 0004 1774 4989. GRID: 
      grid.415130.2
FAU - Notumata, Kazuo
AU  - Notumata K
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, 
      Wadanaka-Machi, Fukui, 918-8503 Japan. ISNI: 0000 0004 1774 4989. GRID: 
      grid.415130.2
FAU - Okafuji, Kazuhiro
AU  - Okafuji K
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, 
      Wadanaka-Machi, Fukui, 918-8503 Japan. ISNI: 0000 0004 1774 4989. GRID: 
      grid.415130.2
FAU - Toya, Daisyu
AU  - Toya D
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, 
      Wadanaka-Machi, Fukui, 918-8503 Japan. ISNI: 0000 0004 1774 4989. GRID: 
      grid.415130.2
LA  - eng
PT  - Journal Article
DEP - 20170103
PL  - Japan
TA  - Diabetol Int
JT  - Diabetology international
JID - 101553224
PMC - PMC6224952
OTO - NOTNLM
OT  - Alanine transaminase
OT  - Ipragliflozin
OT  - L/S ratio on computed tomography
OT  - Type 2 diabetes mellitus
COIS- Yukihiro Bando has served on advisory boards for Astellas Pharma, Inc. Yukihiro 
      Bando has received speaker honoraria from Astellas Pharma, Inc., Eli Lilly Japan 
      K.K., Sanofi K.K., Novo Nordisk Pharma, Ltd., Novartis Pharma K.K., MSD K.K., and 
      Takeda Pharmaceutical Co., Ltd. None of the other authors declare a conflict of 
      interest.All procedures conducted in this study were in accordance with the 
      ethics committee of Fukui-ken Saiseikai Hospital and with the Helsinki 
      Declaration of 1964 and later revision. Informed consent or substitute for it was 
      obtained from all patients for being included in the study. Identifying 
      information of patients of human subjects, including names, initials, addresses, 
      admission dates, hospital numbers, or any other data that might identify patients 
      were not included in our written descriptions.
EDAT- 2017/01/03 00:00
MHDA- 2017/01/03 00:01
PMCR- 2018/01/03
CRDT- 2019/01/04 06:00
PHST- 2016/08/29 00:00 [received]
PHST- 2016/12/20 00:00 [accepted]
PHST- 2019/01/04 06:00 [entrez]
PHST- 2017/01/03 00:00 [pubmed]
PHST- 2017/01/03 00:01 [medline]
PHST- 2018/01/03 00:00 [pmc-release]
AID - 302 [pii]
AID - 10.1007/s13340-016-0302-y [doi]
PST - epublish
SO  - Diabetol Int. 2017 Jan 3;8(2):218-227. doi: 10.1007/s13340-016-0302-y. 
      eCollection 2017 Jun.